Plant-Based Vaccines Market Size, Share & Trends Analysis Distribution by Vaccine Type (Viral Vaccines, Bacterial Vaccines, Parasite & Other Vaccines), Application (Influenza, COVID-19, Veterinary Diseases, Other Infectious Diseases, Therapeutic Vaccines), Source (Tobacco (Nicotiana benthamiana), Cereal Crops (Maize, Rice), Other Plants (Potatoes, Lettuce, Spirulina), Plant Cell Cultures (Carrot, Tobacco)), End-User (Veterinary Sector, Human Healthcare, Research Institutions) and Segment Forecasts, 2025-2034

Global Plant-Based Vaccines Market Size is valued at USD 409.5 Mn in 2024 and is predicted to reach USD 2,161.2 Mn by the year 2034 at an 18.2% CAGR during the forecast period for 2025-2034.

Key Industry Insights & Findings from the Report:

• Growing interest from both the public and private sectors has led to increased investment in plant-based vaccine research and development. This financial support is critical to advancing our technology and bringing our products to market.
• The COVID-19 pandemic has accelerated research into alternative methods of vaccine production, including plant-based platforms. The urgency of developing a vaccine demonstrated the potential of these technologies.
• North America dominated the market and accounted for a revenue share of global revenue in 2024.
• Regulatory approval for plant-based vaccines can be challenging, as regulators may need to establish specific guidelines for this innovative approach. There are limitations, as it takes time to comply with regulatory requirements and to ensure safety and efficacy.

A vital ingredient in the creation of accessible vaccination derivatives is planted life. Plant-based vaccine production reduces the financial burden of infectious diseases in developing countries because of its large production volume and low cost. Numerous clinical trials focus on developing plant-based oral vaccines for therapeutic indications such as influenza, dengue fever, the flu, and the Ebola virus. By avoiding the use of syringes and needles, these immunizations can be given orally, freeing up medical staff for other tasks and reducing the risk of hospitals acquired infections. Due to rising public awareness of these vaccines' benefits and the global spread of infectious diseases, the market for plant-based vaccines is predicted to experience considerable growth during the projection.

Plant-based vaccines are also less expensive and do not require cold-chain shipping. They are easy to store, and adding more space for production is straightforward. The market for vaccines made from plants is expected to grow. To develop plant-based vaccines for various medical applications, the existing and future market participants for plant-based vaccines are concentrating on rigorous clinical practice assessments.

Furthermore, shortly, it was anticipated that the inadequacies, potential for contamination, and environmental issues would restrain the expansion of the global market for plant-based biologics. Pollen can harm non-transgenic harvests, a part of the conventional agricultural exhibition. Pollen contamination incidents in field crop-based Plant Molecular Farming (PMF) outlets, such as those based on maize or rice, expand biosafety situations. Creating recombinant pharmaceutical combinations is now strictly prohibited by U.S. FDA regulations.

Market Segmentation:

The plant-based vaccines market is segmented by vaccine type, application, source, end-user. By vaccine type market is segmented into viral vaccines, bacterial vaccines, parasite & other vaccines. By application, the market is segmented into influenza, COVID-19, veterinary diseases, other infectious diseases, therapeutic vaccines. By source market is segmented into tobacco (nicotiana benthamiana), cereal crops (maize, rice), other plants (potatoes, lettuce, spirulina), plant cell cultures (carrot, tobacco). By end-user, the market is segmented into veterinary sector, human healthcare, and research institutions.

Viral Vaccines Segment is Expected to Drive the Plant-Based Vaccines Market

The viral vaccines segment is the key growth driver in the plant-based vaccines market due to its distinctive technological, safety, and economic benefits. Plant-based systems are particularly adept at manufacturing virus-like particles (VLPs) and viral antigens—non-infectious particles that closely resemble actual viruses and trigger robust immune responses without inducing disease. These platforms facilitate quick genetic modification of plants to express novel viral antigens and are well-suited for addressing new viral threats such as SARS-CoV-2. Plant-derived viral vaccines also present increased safety through the exclusion of human or animal pathogen contamination, greater stability, and efficacy—parameters that are crucial during pandemic preparedness and mass immunization. Their cost-effectiveness and scalability make them even more attractive, particularly for large-scale manufacturing during outbreaks.

Influenza Segment is Growing at the Highest Rate in the Plant-Based Vaccines Market.

The influenza segment of the plant-based vaccines market is witnessing robust growth driven by the rising global prevalence of seasonal influenza, which causes millions of illnesses and significant mortality each year. This chronic public health challenge propels the need for more efficient and accessible vaccines. Plant-based systems provide quick, manufacturable, and economical vaccine production, allowing for timely actions against changing influenza threats. Companies such as Medicago have spearheaded quadrivalent influenza vaccines (QIV) development through plant-based approaches, proving to induce high immune responses against multiple strains. The potential to rapidly develop vaccines to counter seasonal outbreaks and pandemics makes plant-based influenza vaccines an integral part of pandemic preparedness strategies globally.

The North American Plant-Based Vaccines Market Holds A Significant Regional Revenue Share.

The North American plant-based vaccines market is expected to register the highest market share in revenue shortly due to the development of new byproducts. The rising prevalence of influenza conditions in the local market and the expansion of several private and public research organizations dedicated to R&D activities for the development of plant-based vaccines, a massive industrial base, a strong consumer base with high purchasing power, particularly in developed nations like the U.S. and Canada, are other factors contributing to the expansion. Additionally, the Asia Pacific is anticipated to expand significantly over the forecast period due to the rise in infectious disease cases brought on by the climate of the region and the growing popularity of plant-based vaccines over conventional vaccines among the general public.

Recent Developments:

• In Feb 2022, The Canadian government authorized the use of a Covid-19 vaccine derived from plants, providing a novel immunization against the virus. A joint venture between Philip Morris International and a division of Mitsubishi Chemical Holdings Corp. produced the vaccine. Covifenz, a vaccine, was developed through a collaborative effort between GlaxoSmithKline Plc and Medicago Inc., a biopharmaceutical corporation headquartered in Quebec City that is owned by Mitsubishi Chemical and Philip Morris. It was accessible to adults between the ages of 18 and 64, Medicago and Glaxo announced in a joint statement on Thursday.

• In Sept 2021, iBio, a biopharmaceutical business specializing in plant-based technology, obtained a license for an innovative antibody that specifically targets regulatory T cells. The business entered into a global exclusive licensing deal for the advancement and commercialization of RubrYc's monoclonal antibody, RTX-003, which is a potential immunotherapy treatment specifically designed to target regulatory T cells (Tregs).

Competitive Landscape

Some major key players in the Plant-Based Vaccines Market:

• Dow AgroSciences
• Aramis Biotechnologies
• Protalix Biotherapeutics
• iBio Inc. (USA)
• Kentucky BioProcessing (USA)
• Baiya Phytopharm (Thailand)
• Icon Genetics (Germany)
• LenioBio (Germany)
• Lumen Bioscience (USA)
• Leaf Expression Systems (UK)
• ZYUS Life Sciences (Canada)
• PlantForm Corporation (Canada)
• Fraunhofer CMB (USA)
• Mazen Animal Health (USA)
• Other Market Players

Plant-Based Vaccines Market Report Scope: